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Objectives: Pharmacists play a role in providing
medication reconciliation. However, data on
effectiveness on patients’ clinical outcomes appear
inconclusive. Thus, the aim of this study was to
systematically investigate the effect of pharmacist-led
medication reconciliation programmes on clinical
outcomes at hospital transitions.
Design: Systematic review and meta-analysis.
Methods: We searched PubMed, MEDLINE, EMBASE,
IPA, CINHAL and PsycINFO from inception to
December 2014. Included studies were all published
studies in English that compared the effectiveness of
pharmacist-led medication reconciliation interventions
to usual care, aimed at improving medication
reconciliation programmes. Meta-analysis was carried
out using a random effects model, and subgroup
analysis was conducted to determine the sources of
heterogeneity.
Results: 17 studies involving 21 342 adult patients
were included. Eight studies were randomised
controlled trials (RCTs). Most studies targeted multiple
transitions and compared comprehensive medication
reconciliation programmes including telephone follow-
up/home visit, patient counselling or both, during the
first 30 days of follow-up. The pooled relative risks
showed a more substantial reduction of 67%, 28% and
19% in adverse drug event-related hospital revisits (RR
0.33; 95% CI 0.20 to 0.53), emergency department
(ED) visits (RR 0.72; 95% CI 0.57 to 0.92) and
hospital readmissions (RR 0.81; 95% CI 0.70 to 0.95)
in the intervention group than in the usual care group,
respectively. The pooled data on mortality (RR 1.05;
95% CI 0.95 to 1.16) and composite readmission and/
or ED visit (RR 0.95; 95% CI 0.90 to 1.00) did not
differ among the groups. There was significant
heterogeneity in the results related to readmissions and
ED visits, however. Subgroup analyses based on study
design and outcome timing did not show statistically
significant results.
Conclusion: Pharmacist-led medication reconciliation
programmes are effective at improving post-hospital
healthcare utilisation. This review supports the
implementation of pharmacist-led medication
reconciliation programmes that include some
component aimed at improving medication safety.
INTRODUCTION
Medication reconciliation has been recog-
nised as a major intervention tackling the
burden of medication discrepancies and sub-
sequent patient harm at care transitions.1
Unjustifiable medication discrepancies are
responsible for more than half of the medica-
tion errors occurring at transitions in care,
when patients move in and out of hospital or
get transferred to the care of other healthcare
professionals,2 and up to one-third could
have the potential to cause harm.3 Incidence
of unintentional medication changes is
common at care transitions,3–8 and is one of
the reasons for a huge utilisation of health-
care resources.9–13 Medication reconciliation
as a medication safety strategy has been cham-
pioned by a number of healthcare organisa-
tions. It was first adopted in 2005 as a
National Patient Safety Goal (NPSG) by the
Joint Commission14 and, later, the WHO and
collaborators15–17 involved themselves in
endorsing this strategy across many countries.
Strengths and limitations of this study
▪ This is the first systematic review investigating
the effect of pharmacist-led medication reconcili-
ation programmes on clinical outcomes.
▪ In some of the clinical outcomes evaluated, there
is substantial statistical heterogeneity and we
could not identify the source of variation among
the studies.
▪ The inclusion of non-controlled studies might
affect the quality of evidence as seen by the high
risk of bias in these groups of studies.
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Despite these efforts, implementation of a medication
reconciliation service is a hospital-wide challenge,18 and
there is no previous clinical evidence as to which
member of the healthcare profession(s) or which strat-
egies effectively perform medication reconciliation.19 A
number of medication reconciliation strategies have
been utilised for safe patient transitions: use of elec-
tronic reconciliation tools,20–22 standardised forms23 24
and collaborative models,25 26 as well as patient engage-
ment27 and pharmacist-led approaches.28 29
The impact of medication reconciliation on clinical
outcomes at hospital transitions has been reported,
however, two recently published systematic reviews30 31
have ascertained that the benefit as a patient safety strat-
egy is not clear. Both studies have inconsistent findings
on healthcare resource utilisation. Unlike Mueller et al,30
Kwan et al31 did not report significant association
between post-hospital healthcare utilisation and medica-
tion discrepancies identified through medication recon-
ciliation interventions. Both reviews broadly assessed the
effect of medication reconciliation produced by various
strategies, including the use of collaborative models.
The aim of the present review was, thus, to specifically
assess the effectiveness of pharmacist-led medication rec-
onciliation programmes on clinical outcomes during the
transition to and from hospital settings.
METHODS
Data sources and searches
The study was conducted utilising Preferred Reporting
Items for Systematic Reviews and Meta-Analyses
(PRISMA) group guidelines,32 including the PRISMA
checklist, to ensure inclusion of relevant information.
An initial limited search of articles was undertaken and
the search strategy was broadened after analysis of the
text words contained in the title, abstract and index
terms. ‘Medication reconciliation’, ‘medication discrep-
ancies’, ‘medication errors’, ‘medication history’ and
‘pharmac*’, were the main Medicine Subject Headings
(MeSH) and text word terms in the electronic searches.
Then, we carried out a comprehensive search involving
all the collections in the databases until December 2014:
PubMed/MEDLINE (1946), Ovid/MEDLINE (1946),
International Pharmaceutical Abstracts (1970), EMBASE
(1966), PsycINFO (1890) and CINHAL (1937) (see
online supplementary appendix A). The reference
lists of review articles and included studies were manu-
ally searched to locate articles that were not identified in
the database search. Article search was performed by
one reviewer (ABM) with the support of a medical
librarian.
Study selection
To be included in the selection, studies were required to
present the following: papers that reported medication
reconciliation intervention primarily and that provide
data on any of these clinical end points (all-cause
readmission, emergency department (ED) visits, com-
posite rate of readmission and/or ED visits, mortality,
adverse drug event (ADE)-related hospital visit). We
adopted the definition of ‘medication reconciliation’ uti-
lised by the Institute for Healthcare Improvement: ‘the
process of identifying the most accurate list of a patient’s
current medicines including the name, dosage, fre-
quency and route—and comparing them to the current
list in use, recognising and documenting any discrepan-
cies, thus resulting in a complete list of medications’.1
Included studies had to be original peer-reviewed
research articles that were published in English. The
included interventions had to start in the hospital and
be performed primarily by a pharmacist, with the aim of
improving care transitions to and from a hospital. The
intervention had to have been compared with another
group that received usual or standard care. ‘Usual or
standard care’ was defined as any care where targeted
medication reconciliation was not undertaken as an
intervention, or where, if an intervention was con-
ducted, it was not provided by a pharmacist. Along with
duplicate references, and other studies that did not
satisfy the inclusion criteria and were not medication
reconciliation studies, we excluded the following types of
studies: other medication reconciliation practices (eg,
nurse-led) or practices as part of a multicomponent
intervention (eg, medication therapy management),
case studies, systematic reviews, qualitative outcomes and
non-research articles. Abstracts from conferences and
full-texts without raw data available for retrieval were not
considered. Therefore, the studies selected for inclusion
and exclusion assessment were randomised controlled
trials (RCTs), quasi-experimental studies with a control
group, and before-and-after studies that evaluated
pharmacist-led medication reconciliation programmes at
hospital transitions. The titles and abstracts were
screened by one author (ABM), and studies identified
for full-text review and selected according to inclusion
criteria were agreed on by the second (AJM) and third
reviewer (JEB).
Data extraction
One review author (ABM) was responsible for data
extraction from full-texts, using a modified adopted
Cochrane EPOC data collection checklist,33 including
quality assessment of studies. The following information
was extracted from each included study: name of first
author, year of publication, country and setting where
the study was conducted, study design, sample size,
target of intervention, patient characteristics, compo-
nents of intervention, and relevant outcomes and
results. If insufficient details were reported, study
authors were contacted for further information.
Outcomes and statistical analysis
Our analysis included studies that reported at least one
of these end points: healthcare utilisation (readmission,
ED visit and composite readmission, and/or ED visit),
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mortality and ADE-related hospital visits, compared
with usual care in the other arm; and using at least
30 days of follow-up. Studies were eligible for meta-
analysis if such end point could be extractable. We
analysed data in accordance with the Cochrane hand-
book.34 Together with 95% CIs for each outcome,
we derived the relative risk and weighted mean differ-
ences for dichotomous and continuous variables,
respectively.
After we combined data, the analyses were conducted
with Cochrane Review Manager (RevMan) V.5.3 software
(Copenhagen: The Nordic Cochrane Centre, The
Cochrane Collaboration, 2014). We performed separate
analyses for each outcome measured compared with
usual care. We synthesised the results by constructing a
forest plot using a random effects model for each of the
outcomes. We analysed intention-to-treat data whenever
available. The Mantel-Haenszel risk ratio (RR) summary
estimate was determined for outcome measures of
dichotomous variables and the weighted mean differ-
ence was calculated for continuous data variables. To
confirm the reliability of the summary estimate, 95% CIs
were calculated. Since the analyses included medication
reconciliation interventions with multiple components,
different designs and follow-up periods, we set a priori
that might be associated with some variation in the out-
comes between the studies. When there were at least five
studies per outcome, subgroup analyses were carried out
according to methodological design factors (RCT and
non-randomised studies) and outcome timing (duration
of follow-up). For studies that reported outcomes at a
different duration, the longer follow-up period was
taken in the analysis, if there was no difference in the
summary estimate. Otherwise, meta-analysis was per-
formed separately for the long-duration and short-
duration subgroups. We assessed statistical heterogeneity
among studies through calculating τ2, χ2 (Q), I2 and p
value. We conducted sensitivity analysis to check the sta-
bility of summary estimates to outliers and the change in
I2 when any of the studies were withdrawn from the ana-
lysis. We evaluated publication bias by inspection of
funnel plot, and Begg-Mazumdar and Egger’s test using
Comprehensive Meta-analysis, V.3 (Biostat, Englewood,
New Jersey, USA). In all analyses, p value <0.05 was con-
sidered as statistically significant.
We assessed the risk of bias of individual studies with
EPOC risk of bias tool.33 The main domains consid-
ered were random sequence generation, allocation
concealment, blinding of outcome assessment, attrition
and reporting biases. We also determined whether
groups were balanced at baseline in terms of character-
istics and outcomes. Included studies were evaluated
for each domain and a quality scoring was then calcu-
lated for each study. Studies with ‘clear data’ on
each of the domains were given a score of 1, and
studies were assigned a point score out of the
maximum of 9 (9 domains were included in the risk
of bias assessment).
RESULTS
Identification and selection of studies
We identified a total of 2551 citations from searches in
the electronic databases and 59 additional records were
identified in reference lists of included studies. After
removal of duplicate records, title and abstract screen-
ing was applied on 1832 publications. After title and
abstract review, 1731 publications did not meet the
inclusion criteria—the focus for the majority of studies
was not related to medication reconciliation interven-
tions. The remaining 101 publications were obtained in
full-text and assessed for inclusion. Most full-text articles
were excluded either due to reporting of a different
outcome of interest (n=34) or because medication rec-
onciliation was not the primary intervention (n=11)
(see online supplementary appendix B). After applying
all the inclusion criteria, we finally included 17 articles
(figure 1).
Characteristics of included studies
Major characteristics of the included studies are pre-
sented in table 1. They were randomised controlled
trials (n=8, 47%), before-and-after studies (n= 6, 35%)
and non-randomised controlled trials (n= 3, 18%).
The majority of the studies were conducted in the USA
(11 studies),35–45 and the remainder were in Sweden
(3 studies),46–48 Ireland (2 studies)49 50 and Australia
(1 study).51 The studies had been conducted between
2002 and 2014. The included studies involved a total of
21 342 adult patients of various ages with sample sizes
ranging from 41 to 8959 individuals. No studies in paedi-
atrics were identified. Only three studies were confined
to multicentre.38 49 51 Most studies reported outcomes
up to 30 days of follow-up after selection of eligible
patients; only six studies37 46–50 reported longer
follow-up of 3-month or more. Interventions were
initiated at different care transitions; most were con-
ducted at multiple transitions,35 37–40 42 44 46–51 and all
studies targeting a single transition intervention were
carried out at hospital discharge.36 41 43 45
Most studies recruited high-risk patients (including
elderly patients, patients with multiple medications
and patients at risk of medication-related events).
Five studies36 37 39 44 48 focused on a specific patient
population, mainly patients with heart failure and
chronic obstructive pulmonary disease (COPD).
Methodologically, one study35 stratified patients into two
groups: general population and high-risk patients, and
another study37 randomised the population into two
levels of intervention: minimal and enhanced.
Some studies compared comprehensive medication
reconciliation programmes, for example, multifaceted
interventions including telephone follow-up and/or
home visit,44 48 51 and patient counselling,35 38 41 45 or
both telephone/home visit and patient counsel-
ling.37 40 42 43 46 49 50 After medication reconciliation,
a few studies42 46–49 additionally included a
formal medication review. Comparator groups in the
Mekonnen AB, et al. BMJ Open 2016;6:e010003. doi:10.1136/bmjopen-2015-010003 3
Open Access









pen: first published as 10.1136/bm





included studies were varied, and most studies com-
pared medication reconciliation interventions with a
usual care group that did not receive pharmacist-led
intervention.
Risk of bias assessment
Patients included in the study were similar in baseline
characteristics except in five studies,36 38 39 45 48 which
were not clear or different in patient characteristics.
However, in only three studies43 48 51 were baseline
clinical outcomes reported or was some form of adjust-
ment analysis performed. Eight out of 17
studies37 39 40 42 46 49–51 provided enough details on ran-
domisation procedure to be judged as adequate. Among
these studies, allocation concealment was fully described
in all reports except one.51 In all but three
studies43 45 50 had care providers and outcome assessors
been blinded or objective health outcomes reported.
Five studies37 41 47 48 51 achieved more than 80% com-
plete follow-up. However, only a few studies examined
the impact of losses to follow-up or drop-out. High-risk
of contamination was suspected in four studies.35 37 41 47
At least one of our outcomes of interest was selectively
reported in four studies.36 49–51 Overall, on a scale of 9,
quality of randomised controlled trials falls within a
range of 4–8, whereas for non-randomised controlled
trials a lower range of 1–5 score was attained (see online
supplementary appendix C).
Effect of interventions
Of the 14 studies that reported data on all-cause read-
missions, 13 were eligible for meta-analysis. One study35
measured this outcome for a high-risk population
separately; and another study37 reported it for two
different interventions. Thus, 15 interventions were
meta-analysed. Eight studies reported this outcome at
30 days,35 36 39 41 43–45 51 while three46 48 49 reported
long-term data and two studies37 38 reported both.
Seven studies35 38 39 41 44 45 49 showed a significant
reduction (p<0.05) in rehospitalisations although
two39 44 of them had a very small sample size. The
pooled RR (n=21 969 patients) across all studies was
0.81 (95% CI 0.70 to 0.95). However, the results of
these studies for this end point are substantially hetero-
geneous (figure 2A). With regard to all-cause emer-
gency department (ED) contacts, seven of eight
studies35 37–39 43 46 48 that measured ED visit as an
outcome were pooled. Considering studies that gave two
sets of data, nine interventions were meta-analysed. The
pooled analysis across all interventions showed some sig-
nificant difference between the intervention and usual
care (RR 0.72; 95% CI 0.57 to 0.92; figure 2B).
Evidence showed extreme heterogeneity in this
outcome; however, the findings were different when the
study by Gardella et al38 was removed; there was no
heterogeneity without affecting the significance differ-
ence (p=0.25; I2=22%, RR 0.89; 95% CI 0.79 to 0.99).
Figure 1 PRISMA flow diagram
of the selection of eligible studies.
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Nine studies35 37 39 40 42 43 46–48 that reported composite
all-cause readmission and/or ED visit showed no differ-
ence in pooled analysis (RR 0.95; 95% CI 0.90 to 1.00
figure 2C). Only three studies38 42 47 were meta-analysed
for ADE-related hospital revisits. One study46 did not
give data in a suitable form. The pooled result showed a
substantial reduction of 67% in hospital revisits (pooled
RR 0.33; 95% CI 0.20 to 0.53) when pharmacist-led
medication reconciliation programmes were implemen-
ted (figure 2D). Seven studies37 46–51 gave eight separate
sets of data for all-cause mortality that had been
reported after 30 days to 12 months of follow-up.
However, information on mortality from Bolas et al50
and Farris et al37 was not their primary outcome of
interest; nevertheless, we included it in our meta-
analysis. Overall, there was no significance difference
Figure 2 Forest plots of intervention effects on the proportion of patients with all-cause readmission (A), emergency department
(ED) visits (B), composite rate of readmissions and/or ED visits (C), adverse drug event-related hospital revisits (D) and mortality
(E). Pooled estimates (diamond) calculated by the Mantel-Haenszel random effects model. Horizontal bars and diamond widths
represent 95% CIs. Anderegg et al35 stratified patients into two groups: general population and high-risk patients. Farris et al37
randomised the population into different levels of intervention: minimal and enhanced.
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between the two groups in terms of all-cause mortality
(RR 1.05; 95% CI 0.95 to 1.16) (figure 2E).
Other outcomes
Studies reporting other clinically important outcomes
are summarised in table 2. Some studies46–49 furnished
information on the proportion of patients who did not
revisit the hospital. The intervention group in the three
studies46 48 49 showed a trend towards an increase in the
number of patients who did not revisit the hospital for
any causes, and the overall pooled analysis was statistic-
ally significant (RR 1.10; 95% CI 1.03 to 1.17). There
were no significance differences between the interven-
tion and usual care in terms of other relevant clinical
outcomes: length of stay after readmission, readmission
per patient, ED visit per patient and proportion of
patients with ADEs.
Sensitivity analysis
A one-on-one removal of studies in the meta-analysis did
not affect findings in all outcomes except for composite
readmission and/or ED visit. A meta-analysis for com-
posite readmission/ED visit showed that only when the
study by Faris et al (Enhanced)37 or Hawes et al39 was
removed did the result show a significant pooled
summary estimate with similar risk ratio (RR 0.95;
p=0.02 and 0.03, respectively).
Subgroup analysis
Subgroup analysis comparing studies that reported all-
cause readmissions at earlier versus longer follow-up
period showed different patterns of effect: the effect of
intervention was not statistically significant for longer
follow-up subgroups (RR 0.83, 95% CI 0.68 to 1.06,
p=0.14), whereas in earlier follow-up subgroups, the
Figure 2 Continued.





patients RR CI WMD CI
Patients who did not revisit hospital 4 5314 1.10* (1.03 to 1.17)†
Hospital stay (after readmission) 2 803 −0.57 (−5.32 to 4.17)‡
Readmission per patient 3 1370 −0.12 (−0.24 to 0.01)‡
ED visit per patient 2 4342 −0.15 (−0.53 to 0.23)‡
Patients with ADE 3 1401 0.94 (0.75 to 1.20)‡
*RR is >1 when the intervention increased the number of patients who did not revisit the hospital (ie, it showed success).
†p<0.01.
‡p>0.05.
ADE, adverse drug event; ED, emergency department; RR, risk ratio; WMD, weighted mean difference.
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effect was significant (RR 0.77, 95% CI 0.60 to 0.98,
p=0.03). However, there was no significant difference
between these two subgroups. In addition, non-
randomised studies showed a significant reduction in all-
cause readmission (RR 0.74, 95% CI 0.58 to 0.94,
p=0.01) and all-cause ED visit (RR 0.68, 95% CI 0.48 to
0.97, p=0.03), but there was no difference in terms of
study design with these outcomes. As opposed to what
has been observed in the entire analysis, the composite
outcome seemed to have a slight significant reduction in
non-randomised studies (RR 0.95, 95% CI 0.90 to 1.00,
p=0.04); though there was no difference between the
subgroups (see online supplementary appendix D).
Publication bias
We examined the potential for publication bias by con-
structing a funnel plot and through statistical tests.
There was some indication of asymmetry—particularly
for all-cause ED visits—in the funnel plot and, therefore,
there was some publication bias, as evidenced by the
Egger’s (p=0.04) and Begg’s tests (p=0.01) in this
outcome. We did not find any significant evidence of
bias in the other outcomes, as shown by Egger’s test
value of 0.08 for all-cause readmission, 0.57 for compos-
ite readmission/ED visit and 0.83 for all-cause mortality;
this was further supported by Begg’s test p value of 0.13,
0.35 and 0.71, respectively (see online supplementary
appendix E).
DISCUSSION
To the best of our knowledge, this is the first
meta-analysis to investigate the effectiveness of
pharmacist-led medication reconciliation programmes
on clinical outcomes at hospital transitions. This review
has shown better outcomes in favour of pharmacist-led
interventions. We found a substantial reduction in the
rate of all-cause readmissions (19%), all-cause ED visits
(28%) and ADE-related hospital revisits (67%). However,
pooled data on mortality and composite readmission/
ED visit favoured neither the intervention nor the usual
care. Not only were patients allocated to the interven-
tion group readmitted or not only did they revisit the
hospital less frequently, but patients free of any events
after hospital discharge also increased (RR 1.10; 95% CI
1.03 to 1.17).
No previous reviews have conclusively and consistently
shown effectiveness of medication reconciliation inter-
ventions, be it in primary care,52 long-term settings53 or
hospital transitions.30 31 Particularly, reviews from
hospital-initiated medication reconciliation interventions
searched the available literature on medication reconcili-
ation strategies and impact on patient safety, and sum-
marised the evidence that medication reconciliation
alone was not strong enough to reduce post discharge
hospital utilisation.30 31 It was not clear to support the
effectiveness of such interventions in the hospital
setting. However, we believe that the influence of
pharmacist’s in healthcare utilisation was diluted among
those various medication reconciliation strategies and,
thus, specifically assessing the effect of pharmacist in
medication reconciliation is an important consideration.
Although Thomas et al54 did not find a significant
effect in reduction of readmissions due to medication-
related problems, our review showed that pharmacists’
influence in preventing ADE-related hospital revisits was
more impactful than any of the outcomes measured.
This might be because medication reconciliation picks
patients with discontinued medication more powerfully,
where this is the case for studies reporting this
outcome.43 47 Other studies also showed that medication
discontinuity is the most common reason for
discrepancy-related ADE.55 56 Although the study by
Gillespie et al46 was not included in the meta-analysis of
this outcome, it showed a much higher reduction of
80% in medication-related readmissions in the interven-
tion group than in the control group. Readmissions
were frequent in earlier follow-up periods. This is as
opposed to a review by Kwan et al,31 where harm due to
medication discrepancies occurred only some months
after discharge. However, for most studies, the duration
of follow-up was short; only one-third of interventions
followed patients for longer than 30 days. Therefore, it
might be difficult to come to a conclusion, as there was
no sustained benefit from the intervention, and this was
supported by non-significant differences between the
subgroups. Moreover, non-randomised studies showed a
slight significant reduction in all-cause ED visit and
readmission and composite outcome, but there was no
difference in terms of study design with these outcomes.
Otherwise, pooled estimates showed consistent results in
all of these three outcomes, regardless of the study
design and duration of follow-up. However, care should
be taken in interpreting the results as some of the influ-
ence of observational studies on the success of outcome
was clear, and their heterogeneity should be taken into
consideration.
Some of the studies, as part of their intervention, con-
sisted of intermingled components, and the difficulty in
ascertaining the success of pharmacist-led intervention is
due only to medication reconciliation. After medication
reconciliation, for example, medication review as inter-
vention component was added in some studies. Previous
systematic reviews that focused on medication review57 58
raised a debate as to the impact of medication reviews in
general, and pharmacist-led medication reviews in par-
ticular. A review by Holland et al,57 where only 8 of the
32 included studies were hospital-based and only 2 of
these had extensive medical team involvement at hos-
pital transitions, did not support the evidence for
pharmacist-led medication review. On the other hand,
one of the issues raised in a Cochrane review58 was that
medication review had varied and wider meaning, and
did not stand alone. Prior to medication review, it is
medication reconciliation that is practiced routinely at
hospital transitions and, thus, considering medication
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review without ensuring the most accurate list of a
patient’s current medications would be theoretical. This
would strengthen our anticipation that interventions
with medication reconciliation might be as equally
effective as those with mixed interventions.
A number of recent studies have investigated medica-
tion reconciliation interventions at the level of real
practice models or in integrated management of medi-
cines.47–49 Medication reconciliation interventions are
complex interventions targeting fragments of services
across the entire spectrum of care transitions, and thus
take time and effort, but the outcome of safe patient
transition is well worth it. This review further consoli-
dates pharmacist-led medication reconciliation pro-
grammes might contribute to quality transitions in
combinations of those multifaceted components.
Limitation of the study
There are a number of limitations to this study. First,
most studies included high-risk patients, and we did not
confirm which patients benefited most from such inter-
ventions. Various definitions pertaining to high-risk were
employed, including patients with specific disease state,
polypharmacy, older age and patients at risk of hospital-
isation. Second, interventions target different transitions;
we could not take into account this effect in our
meta-analysis. For instance, previous prospective studies
showed varied results on the rate of medication discrep-
ancies from 30–55% during admission,59–62 to 35–71%
during discharge.4 63 64 Coleman et al65 showed that
patients with medication discrepancies have significantly
high rates of readmission. Thus, if this value is extrapo-
lated to clinical outcomes, there might be some vari-
ation among studies with respect to these outcomes at
the different care transitions. Additionally, few studies
were carried out in hospitals where medication reconcili-
ation had already been implemented in some defined
areas. Therefore, future studies should evaluate specific
areas suited to pharmacist services that would benefit
patients the most. Third, most of the studies were single
centre evaluations, and there were a few studies with a
small number of patients. Considering the success rates
within small single centre studies raises an issue about
bias. Our included studies were not free of bias and
most possessed moderate quality, which leaves the find-
ings open to criticism—for example, Gardella et al,38 in
the ADE-related hospital visit, and Hellström et al,48 in
the mortality forest plots, accounted for a large propor-
tion of the studied subjects, yet these studies possessed
low quality score. Fourth, the lack of homogeneity in the
data from this meta-analysis confirms the complexity of
medication reconciliation and warrants further investiga-
tion. We attempted to investigate the sources of variation
between studies, but were unable to explain much of it.
We were also unable to assess interactions between medi-
cation reconciliation and components of interventions.
For example, integrated care models may be particularly
effective for improving care for some of the
interventions, but not for other types, and a pooled ana-
lysis would not identify such interactions. Despite these
limitations, our meta-analyses showed that interventions
that contain one or more elements of medication recon-
ciliation can improve outcomes at hospital transitions.
We also note that only published studies were included
in our work. However, the funnel plot asymmetry and
statistical tests suggest that the impact of bias was less
likely to have a significant effect on the findings. Only
articles published in English were assessed for this
review. Potentially, there may have been studies, such as
that by Sánchez Ulayar et al,66 published in non-English
journals, involving interventions for improving care tran-
sitions. In addition, research disseminated through the
grey literature, such as conference papers and unpub-
lished reports, was not considered.
CONCLUSION
The results of this meta-analysis indicate that a
pharmacist-led medication reconciliation programme at
hospital transitions decreases ADE-related hospital revi-
sits, all-cause readmissions and ED visits. However, the
effect on mortality and composite all-cause readmission/
ED visit is inconclusive based on the current body of evi-
dence, though improvements in the majority of studies
were demonstrated. Future research is needed to assess
whether improvements in such outcomes can be
achieved with this programme and to determine what/
which components of the intervention are necessary to
improve clinical outcomes. Although our results showed
that pharmacist-led medication reconciliation was bene-
ficial at care transitions, we still need further research
with robust, large randomised control trials of excellent
quality to conform our conclusion. Overall, our findings
support the implementation of a pharmacist-led medica-
tion reconciliation programme that includes some com-
ponents aimed at improving medication safety.
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